TRANSGENE: 2017 Full-year results and business update

information fournie par Boursorama •21/03/2018 à 17:45

2017 Full-year results and business update

Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses

* All clinical programs made progress
- 7 clinical trials initiated, including three combination trials in collaboration with Bristol-Myers Squibb and Merck KGaA/Pfizer to access immune checkpoint inhibitors (ICIs) and
two trials evaluating oncolytic viruses
- Clinical results expected in 2018 on five products
* Invir.IO™ oncolytic virus platform launched
- First Invir.IOTM preclinical research agreements signed with BioInvent and Randox
- 10 preclinical product candidates under evaluation
* Good cash position - €41.4 million at the end of 2017 – financial visibility until mid-2019
- Cash burn in 2017 well controlled at €28.1 million

Conference call scheduled today at 6:00 p.m. CET (in English)
.../...